CNTX

Context Therapeutics Inc.

Price Chart

Latest Quote

$0.63

+0.03 (+5.32%)

Current Price

Previous Close	$0.60
Open	$0.61
Day High	$0.64
Day Low	$0.59
Volume	3,050,175

Fetched: 2026-06-19T16:35:21

Stock Information

Shares Outstanding	91.88M
Total Debt	$282K
Cash Equivalents	$54.53M
Net Income	$-40.23M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$58.06M
EPS (TTM)	$-0.42
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$5.50M
Income	$-40.23M
Book/sh	$0.57
Cash/sh	$0.59
Employees	15

Financial Ratios

Quick Ratio	8.35
Current Ratio	8.96
Debt/Eq	0.54

Returns & Margins

ROA	-35.83%
ROE	-56.19%

Ownership

Insider Ownership	1.25%
Institutional Ownership	81.31%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.46
P/B	1.11

Analyst Data

Recommendation	strong_buy
Target Price	$5.43

Technical Indicators

SMA20	$1.87
SMA50	$2.16
SMA200	$1.78
RSI	1.40
ATR	0.2234

Shares Float	42.82M
Short Float	1.12%
Short Ratio	1.35
Volatility	1.61
Rel Volume	1.26

Performance History

Week	-55.49%
Month	-70.88%
Quarter	-78.86%
6 Months	-42.55%
YTD	-59.23%
Year	+9.53%
3 Years	-49.44%
10 Years	-87.61%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$0.63	3,143,700
2026-06-17	$0.60	7,475,800
2026-06-16	$0.65	6,096,500
2026-06-15	$0.68	20,588,800
2026-06-12	$1.39	498,700
2026-06-11	$1.42	558,000
2026-06-10	$1.45	508,500
2026-06-09	$1.52	846,600
2026-06-08	$1.71	629,400
2026-06-05	$1.75	821,600
2026-06-04	$2.03	589,900
2026-06-03	$2.05	906,300
2026-06-02	$2.42	539,500
2026-06-01	$2.79	651,300
2026-05-29	$2.85	552,100
2026-05-28	$2.83	616,700
2026-05-27	$2.98	1,126,200
2026-05-26	$2.63	832,900
2026-05-22	$2.60	1,916,200
2026-05-21	$2.40	986,900
2026-05-20	$2.23	410,300
2026-05-19	$2.17	407,900

About Context Therapeutics Inc.

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

📰 Latest News

CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip

Stocktwits • 2026-06-15T21:20:45Z

Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study

Benzinga • 2026-06-15T15:10:23Z

Positive Signs As Multiple Insiders Buy Context Therapeutics Stock

Simply Wall St. • 2026-04-27T14:15:46Z

Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data

MarketBeat • 2026-03-14T15:32:08Z

Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference

MarketBeat • 2026-03-08T20:02:11Z

Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation

Simply Wall St. • 2026-02-05T16:06:07Z

BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ...

GuruFocus.com • 2025-11-14T05:04:01Z

Institutions profited after Context Therapeutics Inc.'s (NASDAQ:CNTX) market cap rose US$14m last week but private equity firms profited the most

Simply Wall St. • 2025-10-08T10:48:49Z

Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Invest In Growth?

Simply Wall St. • 2025-08-29T15:02:08Z

Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025

Insider Monkey • 2025-07-25T16:22:31Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$39,702,631	$29,923,900	$25,072,616	$14,881,203
Other Income Expense	$200,471	$-1,428	$-55,570	$-502,004
Other Non Operating Income Expenses	$200,471	$-1,428	$-55,570	$-2,004
Net Non Operating Interest Income Expense	$3,378,545	$3,200,224	$1,163,975	$547,268
Operating Expense	$39,702,631	$29,923,900	$25,072,616	$14,881,203
General And Administrative Expense	$7,846,379	$7,222,565	$7,289,885	$7,790,040
Interest Expense	-	-	-	-
Interest Expense Non Operating	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-36,123,615	$-26,725,104	$-23,964,211	$-14,835,939
Net Interest Income	$3,378,545	$3,200,224	$1,163,975	$547,268
Interest Income	$3,378,545	$3,200,224	$1,163,975	$547,268
Normalized Income	$-36,123,615	$-26,725,104	$-23,964,211	$-14,335,939
Net Income From Continuing And Discontinued Operation	$-36,123,615	$-26,725,104	$-23,964,211	$-14,835,939
Total Operating Income As Reported	$-39,702,631	$-29,923,900	$-25,072,616	$-15,381,203
Net Income Common Stockholders	$-36,123,615	$-26,725,104	$-23,964,211	$-14,835,939
Net Income	$-36,123,615	$-26,725,104	$-23,964,211	$-14,835,939
Net Income Including Noncontrolling Interests	$-36,123,615	$-26,725,104	$-23,964,211	$-14,835,939
Net Income Continuous Operations	$-36,123,615	$-26,725,104	$-23,964,211	$-14,835,939
Pretax Income	$-36,123,615	$-26,725,104	$-23,964,211	$-14,835,939
Interest Income Non Operating	$3,378,545	$3,200,224	$1,163,975	$547,268
Operating Income	$-39,702,631	$-29,923,900	$-25,072,616	$-14,881,203
Special Income Charges	-	-	$0	$-500,000
Per Share
Diluted EPS	$-0.38	$-0.46	$-1.50	$-0.93
Basic EPS	$-0.38	$-0.46	$-1.50	$-0.93
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-39,686,380	$-29,913,019	$-25,060,572	$-14,371,935
Reconciled Depreciation	$16,251	$10,881	$12,044	$9,268
EBITDA (Bullshit earnings)	$-39,686,380	$-29,913,019	$-25,060,572	$-14,871,935
EBIT	$-39,702,631	$-29,923,900	$-25,072,616	$-14,881,203
Diluted Average Shares	$95,185,683	$58,416,141	$15,966,053	$15,966,053
Basic Average Shares	$95,185,683	$58,416,141	$15,966,053	$15,966,053
Diluted NI Availto Com Stockholders	$-36,123,615	$-26,725,104	$-23,964,211	$-14,835,939
Research And Development	$31,856,252	$22,701,335	$17,782,731	$7,091,163
Selling General And Administration	$7,846,379	$7,222,565	$7,289,885	$7,790,040
Other Gand A	$7,846,379	$7,222,565	$7,289,885	$7,790,040
Total Unusual Items	-	-	$0	$-500,000
Total Unusual Items Excluding Goodwill	-	-	$0	$-500,000
Other Special Charges	-	-	-	$500,000
Restructuring And Mergern Acquisition	-	-	-	-
Gain On Sale Of Security	-	-	-	-

Fetched: 2026-06-18

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$60,473,727	$95,266,262	$11,871,020	$34,758,366
Total Assets	$68,493,768	$98,126,759	$16,062,735	$37,965,943
Total Non Current Assets	$140,066	$230,775	$15,524	$112,285
Current Assets	$68,353,702	$97,895,984	$16,047,211	$37,853,658
Other Current Assets	$2,358,474	$3,466,160	$1,597,384	$2,356,213
Cash Cash Equivalents And Short Term Investments	$65,995,228	$94,429,824	$14,449,827	$35,497,445
Cash And Cash Equivalents	$65,995,228	$94,429,824	$14,449,827	$35,497,445
Other Non Current Assets	-	-	-	$32,750
Non Current Deferred Assets	-	-	-	-
Prepaid Assets	-	-	-	-
Debt
Total Debt	$112,064	$219,380	$0	$55,078
Long Term Debt And Capital Lease Obligation	$0	$112,064	$0	-
Current Debt And Capital Lease Obligation	$112,064	$107,316	-	$55,078
Liabilities
Total Liabilities Net Minority Interest	$8,020,041	$2,860,497	$4,191,715	$3,207,577
Total Non Current Liabilities Net Minority Interest	$0	$112,064	$0	$0
Current Liabilities	$8,020,041	$2,748,433	$4,191,715	$3,207,577
Other Current Liabilities	$38,968	$49,779	$8,493	$83,456
Payables And Accrued Expenses	$6,484,579	$1,699,421	$3,530,418	$2,298,988
Payables	$2,532,887	$1,452,188	$2,383,016	$936,330
Accounts Payable	$2,532,887	$1,452,188	$2,383,016	$936,330
Equity
Common Stock Equity	$60,473,727	$95,266,262	$11,871,020	$34,758,366
Total Equity Gross Minority Interest	$60,473,727	$95,266,262	$11,871,020	$34,758,366
Stockholders Equity	$60,473,727	$95,266,262	$11,871,020	$34,758,366
Retained Earnings	$-130,903,309	$-94,779,694	$-68,054,590	$-44,090,379
Preferred Securities Outside Stock Equity	-	-	-	-
Other
Ordinary Shares Number	$91,879,177	$89,704,194	$15,966,053	$15,966,053
Share Issued	$91,879,177	$89,704,194	$15,966,053	$15,966,053
Tangible Book Value	$60,473,727	$95,266,262	$11,871,020	$34,758,366
Invested Capital	$60,473,727	$95,266,262	$11,871,020	$34,758,366
Working Capital	$60,333,661	$95,147,551	$11,855,496	$34,646,081
Capital Lease Obligations	$112,064	$219,380	$0	$55,078
Total Capitalization	$60,473,727	$95,266,262	$11,871,020	$34,758,366
Additional Paid In Capital	$191,285,157	$189,956,252	$79,909,644	$78,832,779
Capital Stock	$91,879	$89,704	$15,966	$15,966
Common Stock	$91,879	$89,704	$15,966	$15,966
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$0	$112,064	$0	-
Current Capital Lease Obligation	$112,064	$107,316	$0	$55,078
Pensionand Other Post Retirement Benefit Plans Current	$1,384,430	$891,917	$652,804	$770,055
Current Accrued Expenses	$3,951,692	$247,233	$1,147,402	$1,362,658
Net PPE	$140,066	$230,775	$15,524	$79,535
Gross PPE	$140,066	$230,775	$15,524	$79,535
Other Properties	$140,066	$230,775	$15,524	$79,535
Treasury Shares Number	-	-	$0	-

Fetched: 2026-06-18

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-28,419,328	$-29,313,750	$-21,047,618	$-14,086,070
Operating Activities
Operating Cash Flow	$-26,385,380	$-14,556,434	$-21,047,618	$-13,549,234
Cash Flow From Continuing Operating Activities	$-26,385,380	$-14,556,434	$-21,047,618	$-13,549,234
Operating Gains Losses	$108,406	$41,822	$51,967	$78,521
Investing Activities
Capital Expenditure	$-2,033,948	$-14,757,316	-	$-536,836
Investing Cash Flow	$-2,033,948	$-14,757,316	$0	$-536,836
Cash Flow From Continuing Investing Activities	$-2,033,948	$-14,757,316	$0	$-536,836
Financing Activities
Issuance Of Capital Stock	$0	$109,293,747	$0	$0
Financing Cash Flow	$-15,268	$109,293,747	$0	$-102,071
Cash Flow From Continuing Financing Activities	$-15,268	$109,293,747	$0	$-102,071
Net Other Financing Charges	$-15,268	-	-	$-102,071
Net Common Stock Issuance	$0	$109,293,747	$0	$0
Common Stock Issuance	$0	$109,293,747	$0	$0
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Other
End Cash Position	$65,995,228	$94,429,824	$14,449,827	$35,497,445
Beginning Cash Position	$94,429,824	$14,449,827	$35,497,445	$49,685,586
Changes In Cash	$-28,434,596	$79,979,997	$-21,047,618	$-14,188,141
Net Intangibles Purchase And Sale	$-2,000,000	$-14,750,000	$0	$-500,000
Purchase Of Intangibles	$-2,000,000	$-14,750,000	$0	$-500,000
Net PPE Purchase And Sale	$-33,948	$-7,316	$0	$-36,836
Purchase Of PPE	$-33,948	$-7,316	$0	$-36,836
Change In Working Capital	$6,282,498	$-3,475,900	$1,775,717	$-277,524
Change In Other Current Liabilities	$-107,316	$-41,258	$-55,078	$-75,410
Change In Payables And Accrued Expense	$5,282,128	$-1,565,866	$1,039,216	$566,685
Change In Accrued Expense	$4,186,161	$-619,770	$-407,470	$1,354,578
Change In Payable	$1,095,967	$-946,096	$1,446,686	$-787,893
Change In Account Payable	$1,095,967	$-946,096	$1,446,686	$-787,893
Change In Prepaid Assets	$1,107,686	$-1,868,776	$758,829	$-736,049
Other Non Cash Items	$2,000,000	$14,750,000	-	$500,000
Stock Based Compensation	$1,331,080	$841,867	$1,076,865	$976,440
Depreciation Amortization Depletion	$16,251	$10,881	$12,044	$9,268
Depreciation And Amortization	$16,251	$10,881	$12,044	$9,268
Gain Loss On Sale Of PPE	$108,406	$41,822	$51,967	$78,521
Net Income From Continuing Operations	$-36,123,615	$-26,725,104	$-23,964,211	$-14,835,939
Change In Other Current Assets	-	$0	$32,750	$-32,750
Issuance Of Debt	-	-	-	-
Net Issuance Payments Of Debt	-	-	-	-
Net Long Term Debt Issuance	-	-	-	-
Long Term Debt Issuance	-	-	-	-
Gain Loss On Investment Securities	-	-	-	-

Fetched: 2026-06-18